Your browser doesn't support javascript.
loading
Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder.
Farhat, Luis C; Vattimo, Edoardo F Q; Ramakrishnan, Divya; Levine, Jessica L S; Johnson, Jessica A; Artukoglu, Bekir B; Landeros-Weisenberger, Angeli; Asbahr, Fernando R; Cepeda, Sandra L; Comer, Jonathan S; Fatori, Daniel; Franklin, Martin E; Freeman, Jennifer B; Geller, Daniel A; Grant, Paul J; Goodman, Wayne K; Heyman, Isobel; Ivarsson, Tord; Lenhard, Fabian; Lewin, Adam B; Li, Fenghua; Merlo, Lisa J; Mohsenabadi, Hamid; Peris, Tara S; Piacentini, John; Rosa-Alcázar, Ana I; Rosa-Alcázar, Àngel; Rozenman, Michelle; Sapyta, Jeffrey J; Serlachius, Eva; Shabani, Mohammad J; Shavitt, Roseli G; Small, Brent J; Skarphedinsson, Gudmundur; Swedo, Susan E; Thomsen, Per Hove; Turner, Cynthia; Weidle, Bernhard; Miguel, Euripedes C; Storch, Eric A; Mataix-Cols, David; Bloch, Michael H.
Afiliação
  • Farhat LC; Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.
  • Vattimo EFQ; Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.
  • Ramakrishnan D; Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut.
  • Levine JLS; Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut.
  • Johnson JA; Columbia University New York, New York; Columbia School of Nursing, New York.
  • Artukoglu BB; SUNY Downstate Health Sciences University, New York.
  • Landeros-Weisenberger A; Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut.
  • Asbahr FR; Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.
  • Cepeda SL; Baylor College of Medicine, Texas.
  • Comer JS; Center for Children and Families, Florida International University, Miami, Florida.
  • Fatori D; Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.
  • Franklin ME; University of Pennsylvania, Philadelphia; Rogers Memorial Hospital, Oconomowoc, Wisconsin.
  • Freeman JB; Warren Alpert Medical School, Brown University, Providence, Rhode Island.
  • Geller DA; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Grant PJ; Washington, DC.
  • Goodman WK; Baylor College of Medicine, Texas.
  • Heyman I; Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom.
  • Ivarsson T; Regional Center for Child and Youth Mental Health and Child Welfare, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
  • Lenhard F; Centre for Psychiatry Research, Karolinska Institutet, Stockholm Health Care Services, Region Stockholm, Sweden.
  • Lewin AB; University of South Florida, Hillsborough County.
  • Li F; Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut.
  • Merlo LJ; University of Florida, Miami.
  • Mohsenabadi H; Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, IR.
  • Peris TS; Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles.
  • Piacentini J; Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles.
  • Rosa-Alcázar AI; University of Murcia, Spain.
  • Rosa-Alcázar À; University of Murcia, Spain.
  • Rozenman M; University of Denver, Colorado.
  • Sapyta JJ; Duke University School of Medicine, Durham, North Carolina.
  • Serlachius E; Centre for Psychiatry Research, Karolinska Institutet, Stockholm Health Care Services, Region Stockholm, Sweden.
  • Shabani MJ; Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, IR.
  • Shavitt RG; Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.
  • Small BJ; School of Aging Studies, University of South Florida, Hillsborough County.
  • Skarphedinsson G; Faculty of Psychology, University of Iceland, Reykjavik.
  • Swedo SE; National Institutes of Health, Bethesda, Maryland.
  • Thomsen PH; Regional Center for Child and Youth Mental Health and Child Welfare, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Aarhus University Hospital, Skejby, Denmark.
  • Turner C; Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Weidle B; Regional Center for Child and Youth Mental Health and Child Welfare, Faculty of Medicine and Health Science, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; St. Olav's University Hospital, Trondheim, Norway.
  • Miguel EC; Faculdade de Medicina FMUSP, Universidade de São Paulo, Brazil.
  • Storch EA; Baylor College of Medicine, Texas.
  • Mataix-Cols D; Centre for Psychiatry Research, Karolinska Institutet, Stockholm Health Care Services, Region Stockholm, Sweden.
  • Bloch MH; Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut. Electronic address: michael.bloch@yale.edu.
J Am Acad Child Adolesc Psychiatry ; 61(4): 495-507, 2022 04.
Article em En | MEDLINE | ID: mdl-34597773
ABSTRACT

OBJECTIVE:

A lack of universal definitions for response and remission in pediatric obsessive-compulsive disorder (OCD) has hampered the comparability of results across trials. To address this problem, we conducted an individual participant data diagnostic test accuracy meta-analysis to evaluate the discriminative ability of the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) in determining response and remission. We also aimed to generate empirically derived cutoffs on the CY-BOCS for these outcomes.

METHOD:

A systematic review of PubMed, PsycINFO, Embase and CENTRAL identified 5,401 references; 42 randomized controlled clinical trials were considered eligible, and 21 provided data for inclusion (N = 1,234). Scores of ≤2 in the Clinical Global Impressions Improvement and Severity scales were chosen to define response and remission, respectively. A 2-stage, random-effects meta-analysis model was established. The area under the curve (AUC) and the Youden Index were computed to indicate the discriminative ability of the CY-BOCS and to guide for the optimal cutoff, respectively.

RESULTS:

The CY-BOCS had sufficient discriminative ability to determine response (AUC = 0.89) and remission (AUC = 0.92). The optimal cutoff for response was a ≥35% reduction from baseline to posttreatment (sensitivity = 83.9, 95% CI = 83.7-84.1; specificity = 81.7, 95% CI = 81.5-81.9). The optimal cutoff for remission was a posttreatment raw score of ≤12 (sensitivity = 82.0, 95% CI = 81.8-82.2; specificity = 84.6, 95% CI = 84.4-84.8).

CONCLUSION:

Meta-analysis identified empirically optimal cutoffs on the CY-BOCS to determine response and remission in pediatric OCD randomized controlled clinical trials. Systematic adoption of standardized operational definitions for response and remission will improve comparability across trials for pediatric OCD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Obsessivo-Compulsivo Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Systematic_reviews Limite: Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Obsessivo-Compulsivo Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Systematic_reviews Limite: Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article